BCL6 and Autoimmunity: To focus on this latter possibility (which would support BCL6 targeting in human T1D after B cell autoimmunity for insulin/islet autoantigens is established), we deploy the VH125SD.NOD model, in which a 1-3% population of insulin-binding B cells forms in the bone marrow that seeds the periphery and supports accelerated diabetes onset 41.